Nutraplus India Faces Financial Collapse Amid Asset Seizure and Mounting Losses

Nutraplus India reported a net loss of ₹0.36 crore on total income of ₹0.10 crore for the quarter ended September 30, 2025. Revenue climbed to ₹0.10 crore, up from nil in the same period last year. This marks a slight positive trend, overshadowed by severe financial distress.

Latest Financial Results

Nutraplus India has released its financial results for the quarter ended September 30, 2025 (Q2 FY26) and the full fiscal year ended March 31, 2025 (FY25).

For the quarter, total income was ₹0.10 crore (9.67 Lacs), a significant increase from nil in the same quarter last year. Total expenses reached ₹0.46 crore (45.53 Lacs), resulting in a net loss of ₹0.36 crore (35.85 Lacs). Earnings per share (EPS) stood at a negative ₹0.11.

For the full fiscal year 2025, Nutraplus India recorded nil total income and total expenses of ₹0.05 crore (5.01 Lacs), leading to a net loss of ₹0.05 crore (5.01 Lacs).

Significance of the Financial Health

These results highlight Nutraplus India's dire financial health. The company faces extreme distress, marked by a rapidly worsening net worth and the critical seizure of its assets.

A qualified audit report adds to the uncertainty, as auditors could not obtain all necessary financial data, impacting disclosure reliability.

Asset Seizure and Operational Halt

Nutraplus India's core manufacturing assets, including property, plant, and equipment, have been seized. This action follows the company's NPA declaration in FY 2019-20 and occurred under the SARFEASI Act, 2002, severely impacting its operational capabilities.

The SARFAESI Act allows secured creditors to enforce security interests without court intervention, accelerating the recovery of defaulting loans and NPAs.

Key Impacts on Shareholders

• Shareholders now face a company whose operational assets have been confiscated by banks.
• The balance sheet is severely weakened by a deep negative net worth and significant liabilities.
• Future viability is questionable due to auditors' inability to conduct a complete review.
• The stock could face increased scrutiny from regulators and exchanges due to ongoing compliance issues.

Key Risks and Financial Weaknesses

• Negative Net Worth: Total equity is a substantial ₹5.72 crore negative as of September 30, 2025, worsening from ₹5.35 crore at FY25 end.
• Asset Seizure: All property, plant, and equipment are lost due to NPA status and SARFEASI Act action.
• Qualified Audit: Auditors could not obtain all required financial data, and compliance with listing norms is lacking.
• Escalating Losses: The quarterly net loss significantly increased year-on-year.
• High Liabilities: Significant trade payables (₹8.45 crore) and borrowings (₹2.23 crore) remain with no property assets available.
• Past Regulatory Issues: SEBI has previously penalized entities for fraudulent trading and manipulation concerning the company's stock.

Comparison with Peers

While direct pharmaceutical peers are few for this small-cap, companies like Lords Chloro Alkali Ltd and Nirali Nitrile Ltd operate in manufacturing sectors with comparable market caps. However, Nutraplus India's situation is uniquely precarious due to its NPA status and asset seizure, challenges not common for these peers. Larger pharma players such as Ajanta Pharma Ltd present a stark contrast in financial stability.

Key Financial Metrics

• Standalone Net Loss for Q2 FY26: ₹0.36 crore (35.85 Lacs).
• Standalone Total Income for Q2 FY26: ₹0.10 crore (9.67 Lacs).
• Standalone Total Equity as of September 30, 2025: Negative ₹5.72 crore (571.52 Lacs).

What to Watch For

• Any potential resolution or company communication regarding the asset seizure.
• The company's ability to comply with listing requirements and provide complete financial data to auditors.
• Future quarterly results to gauge if the minor revenue growth is sustained or reversed.
• Any regulatory actions or exchange notices concerning the company's financial standing.
• Developments concerning the significant trade payables and borrowings on its balance sheet.